Cardiac arrhythmias and diabetes mellitus: What a clinician needs to know
https://doi.org/10.62751/2713-0177-2025-6-2-05
Abstract
Despite a comprehensive study of such comorbidities as cardiovascular diseases and diabetes mellitus (DM), the pathogenetic mechanisms and clinical course of cardiac arrhythmias in this pathology require more detailed research. Cardiac arrhythmias are the leading cause of sudden cardiac death in patients with diabetes, presenting a serious clinical problem. The pathogenesis of arrhythmias in DM is complex and multifaceted. Numerous risk factors, including chronic hyperglycemia, create a background for structural remodeling of the myocardium, which is an early marker of heart muscle dysfunction. Concurrently, dysregulation of the autonomic nervous system leads to significant changes in the electrical activity of the heart and causes rhythm disorders. The variety of arrhythmias, including supraventricular and ventricular arrhythmias as well as bradyarrhythmias, creates significant diagnostic and therapeutic challenges for medical professionals and necessitates an integrated approach to diagnosing this category of patients. Understanding the mechanisms of arrhythmia development in DM is crucial for their effective prevention and treatment. This review examines the pathophysiological mechanisms underlying arrhythmias in DM and identifies the main therapeutic goals for reducing the risk of sudden cardiac death.
About the Authors
M. N. Nadybina
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Margarita N. Nadybina – graduate student of the Department of endocrinology
Moscow
F. O. Ushanova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Fatima O. Ushanova – C. Sci. (Med.), Associate Professor of the Department of endocrinology
Moscow
T. Ya. Izmaylova
Russian University of Medicine
Russian Federation
Russian Federation
Tamara Y. Izmailova – student
Moscow
References
1. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium; 2021. URL: https://www.diabetesatlas.org (date of access – 02.04.2025).
2. Marx N, Federici M, Schutt K et al.; ESC Scientific Document Group. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39): 4043–40. doi: 10.1093/eurheartj/ehad192.
3. Remme CA. Sudden cardiac death in diabetes and obesity: Mechanisms and therapeutic strategies. Can J Cardiol. 2022; 38(4): 418–26.doi: 10.1016/j.cjca.2022.01.001.
4. Zaccardi F, Khan H, Laukkanen JA. Diabetes mellitus and risk of sudden cardiac death: a systematic review and meta-analysis. Int J Cardiol. 2014; 177(2): 535–37. doi: 10.1016/j.ijcard.2014.08.105.
5. Homan EA, Reyes MV, Hickey KT, Morrow JP. Clinical overview of obesity and diabetes mellitus as risk factors for atrial fibrillation and sudden cardiac death. Front Physiol. 2019; 9: 1847. doi: 10.3389/fphys.2018.01847.
6. Fatemi O, Yuriditsky E, Tsioufis C et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol. 2014; 114(8): 1217–22. doi: 10.1016/j.amjcard.2014.07.045.
7. Go AS, Hlatky MA, Liu TI et al. Contemporary burden and correlates of symptomatic paroxysmal supraventricular tachycardia. J Am Heart Assoc. 2018; 7(14): e008759. doi: 10.1161/JAHA.118.008759.
8. Chen-Scarabelli C, Scarabelli TM. Suboptimal glycemic control, independently of QT interval duration, is associated with increased risk of ventricular arrhythmias in a high-risk population. Pacing Clin Electrophysiol. 2006; 29(1): 9–14. doi: 10.1111/j.1540-8159.2006.00298.x.
9. Gorenek B, Boriani G, Dan GA et al.; ESC Scientific Document Group. European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). Europace. 2018; 20(6): 895–96. doi: 10.1093/europace/euy051. Erratum in: Europace. 2018; 20(6): 948. doi: 10.1093/europace/euy103.
10. Tse G, Lai ET, Tse V, Yeo JM. Molecular and electrophysiological mechanisms underlying cardiac arrhythmogenesis in diabetes mellitus. J Diabetes Res. 2016; 2016: 2848759. doi: 10.1155/2016/2848759.
11. Sedgwick B, Riches K, Bageghni SA et al. Investigating inherent functional differences between human cardiac fibroblasts cultured from nondiabetic and Type 2 diabetic donors. Cardiovasc Pathol. 2014; 23(4): 204–10. doi: 10.1016/j.carpath.2014.03.004.
12. Нуждина Е.В., Давыдова Е.В. Автономная кардиальная нейропатия и ремоделирование миокарда левого желудочка у пациентов с сахарным диабетом и сопутствующими болезнями системы кровообращения и почек. Профилактическая медицина. 2020; 23(1): 131–138. doi: 10.17116/profmed202023011127.
13. Pop-Busui R, Braffett BH, Zinman B et al. Cardiovascular autonomic neuropathy and cardiovascular outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Care. 2016; 40(1): 94–100. doi: 10.2337/dc16-1397.
14. Secrest AM, Becker DJ, Kelsey SF et al. Characterizing sudden death and dead-in-bed syndrome in Type 1 diabetes: Analysis from two childhood-onset Type 1 diabetes registries. Diabet Med. 2011; 28(3): 293–300. doi: 10.1111/j.1464-5491.2010.03154.x.
15. Mellbin LG, Ryden L, Riddle MC et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J. 2013; 34(40): 3137–44. doi: 10.1093/eurheartj/eht332.
16. Andersen A, Bagger JI, Sørensen SK et al. Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: A prospective, observational study. Cardiovasc Diabetol. 2021; 20(1): 241. doi: 10.1186/s12933-021-01425-0.
17. Finocchiaro G, Papadakis M, Dhutia H et al. Obesity and sudden cardiac death in the young: Clinical and pathological insights from a large national registry. Eur J Prev Cardiol. 2018; 25(4): 395–401. doi: 10.1177/2047487317751291.
18. Laurita KR, Khan S, McMahon T et al. Ventricular arrhythmias in mouse models of diabetic kidney disease. Sci Rep. 2021; 11(1): 20570.doi: 10.1038/s41598-021-99891-9.
19. Cosentino F, Grant PJ, Aboyans V et al.; ESC Scientific Document Group. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255–323. doi: 10.1093/eurheartj/ehz486. Erratum in: Eur Heart J. 2020; 41(45): 4317. doi: 10.1093/eurheartj/ehz828.
20. Ушанова Ф. О., Измайлова М. Я., Надыбина М. Н. Нарушения сердечного ритма у пациентов с сахарным диабетом 2 типа. FOCUS Эндокринология. 2024; 5(2): 12–18. doi: 10.62751/2713-0177-2024-5-2-12.
21. Patel MR, Mahaffey KW, Garg J et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–91. doi: 10.1056/ NEJMoa1009638.
22. Клинические рекомендации Министерства здравоохранения РФ: Фибрилляция и трепетание предсердий. 2020; с 76.
23. Клинические рекомендации Министерства здравоохранения РФ: Брадиаритмии и нарушения проводимости. 2020; с. 28.
24. Моргунов Л. Ю. Сахарный диабет и нарушения ритма сердца. Лечащий врач. 2024; 27(3): 7–15. doi: 10.51793/OS.2024.27.3.001.
25. Neal B, Perkovic V, Mahaffey KW et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377(7): 644–57. doi: 10.1056/NEJMoa1611925.
26. Zelniker TA, Bonaca MP, Furtado RHM et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: Insights from the DECLARE-TIMI 58 trial. Circulation. 2020; 141(15): 1227–34. doi: 10.1161/CIRCULATIONAHA.119.044183.
27. Zhong J, Chen H, Liu Q et al. GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation. J Pharm Anal. 2024; 14(5): 100917. doi: 10.1016/j.jpha.2023.12.007.
28. Zinman B, Wanner C, Lachin JM et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117–28. doi: 10.1056/NEJMoa1504720.
29. Marso SP, Daniels GH, Brown-Frandsen K et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375(4): 311–22. doi: 10.1056/NEJMoa1603827.
30. Liou YS, Yang FY, Chen HY, Jong GP. Antihyperglycemic drugs use and new-onset atrial fibrillation: A population-based nested case control study. PLoS One. 2018; 13(8): e0197245. doi: 10.1371/journal.pone.0197245.
31. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131): 854–65.
32. Lv R, Xu L, Che L et al. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. Front Endocrinol (Lausanne). 2023; 14: 1125693. doi: 10.3389/fendo.2023.1125693.
33. Filippatos G, Bakris GL, Pitt B et al. Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J Am Coll Cardiol. 2021; 78(2): 142–52. doi: 10.1016/j.jacc.2021.04.079.
Review
For citations:
Nadybina M.N., Ushanova F.O., Izmaylova T.Ya. Cardiac arrhythmias and diabetes mellitus: What a clinician needs to know. FOCUS. Endocrinology. 2025;6(2):38–46. (In Russ.) https://doi.org/10.62751/2713-0177-2025-6-2-05
Views:
66
Email this article 